2
项与 Fecal Microbiota(McGill University Health Centre) 相关的临床试验Fecal Microbiota Transplantation to Reduce Immune Activation in ART-treated People Living With HIV With Low CD4/CD8 Ratio: The Gutsy Study
The goal of this randomized, single blind, two-armed pilot study is to assess the efficacy of FMT in reducing gut mucosal and systemic inflammation in ART-treated people living with HIV with low CD4/CD8 ratio. The main questions it aims to answer are: •Is there a change in the gut permeability among participants taking FMT compared to placebo? • Has inflammation been reduced by the use of FMT? Ten participants will be randomized to receive FMT in capsules, and another 10 participants will receive placebo capsules containing microcrystalline cellulose. Capsules will be given twice (30 to 40 capsules at each treatment) at 3 weeks interval, to ensure engraftment. In an optional substudy, participants will be asked to undergo colonoscopy before and 3 months after FMT to assess gut inflammation and HIV reservoir size in colon biopsies. Researchers will compare the FMT arm and the Placebo arm to see if there are differences in gut permeability and inflammation.
Clinical study of FMT Capsules on cancer immunotherapy
100 项与 Fecal Microbiota(McGill University Health Centre) 相关的临床结果
100 项与 Fecal Microbiota(McGill University Health Centre) 相关的转化医学
100 项与 Fecal Microbiota(McGill University Health Centre) 相关的专利(医药)
100 项与 Fecal Microbiota(McGill University Health Centre) 相关的药物交易